3D Printing and Nanotechnology: A Multiscale Alliance in Personalized Medicine
Source abstract
Abstract
Abstract 3D printing and nanotechnology have been two important tools in the development of therapeutic approaches for personalized medicine. More recently, their alliance has been improved in an effort to build innovative, versatile, multifunctional, and/or smart medical and pharmaceutical products. Therefore, an extensive review about scientific studies that ally 3D printing and nanomaterials in the development of new approaches for pharmaceutical and medical applications for the treatment and prevention of diseases is presented here. The articles are classified into five categories according to their main application: Cell growth and tissue engineering, antimicrobial, drug delivery, stimulus‐response, and theranostics. Semisolid extrusion, inorganic nanoparticles, and cell growth and tissue engineering are the most reported 3D printing technique, type of nanomaterial, and application, respectively. The increase in papers dedicated to these areas is also notable, especially in the 2019 and 2020, when semisolid extrusion became the most used technique, overcoming fused deposition modelling. In fact, this review highlights that the possibility of an alliance between 3D printing and nanotechnology for the production of multiscale materials is undoubtedly a great opportunity for knowledge and innovation in the pharmaceutical and medical area.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Bone Tissue Engineering Materials · Additive Manufacturing and 3D Printing Technologies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Programa de Pós‐Graduação em Ciências Farmacêuticas Universidade Federal do Rio Grande do Sul Avenida Ipiranga, 2752 Porto Alegre Rio Grande do Sul 90610‐000 Brazil
Departamento de Produção e Controle de Medicamentos Universidade Federal do Rio Grande do Sul Avenida Ipiranga, 2752 Porto Alegre Rio Grande do Sul 90610‐000 Brazil
Funding
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
References (100+)
Show source-provided references
1. 10.1088/1758-5090/aa727910.1088/1758-5090/aa7279 ↗
2. 10.1007/s11095-018-2454-x10.1007/s11095-018-2454-x ↗
3. 10.1016/j.apmt.2020.10070010.1016/j.apmt.2020.100700 ↗
4. 10.1016/j.tips.2018.02.00610.1016/j.tips.2018.02.006 ↗
5. Park B. J. · J. Pharm. Invest. · 2019 · 49 · 575
6. 10.1016/j.addma.2020.10120910.1016/j.addma.2020.101209 ↗
7. 10.1016/j.amjmed.2020.04.00210.1016/j.amjmed.2020.04.002 ↗
8. 10.1186/s41205-020-00064-710.1186/s41205-020-00064-7 ↗
9. 10.1080/17425247.2017.137169810.1080/17425247.2017.1371698 ↗
10. 10.3390/nano901009610.3390/nano9010096 ↗
11. 10.2217/nnm-2017-036910.2217/nnm-2017-0369 ↗
12. 10.1002/btm2.1014310.1002/btm2.10143 ↗
13. 10.1007/s11095-016-1958-510.1007/s11095-016-1958-5 ↗
14. 10.1002/wnan.141610.1002/wnan.1416 ↗
15. Ventola C. L. · P&T · 2017 · 42 · 742
16. 10.1016/j.ijpharm.2015.04.06910.1016/j.ijpharm.2015.04.069 ↗
17. 10.1016/j.ijpharm.2017.05.07410.1016/j.ijpharm.2017.05.074 ↗
18. 10.1016/j.jddst.2020.10162510.1016/j.jddst.2020.101625 ↗
19. 10.1002/jbm.a.3691410.1002/jbm.a.36914 ↗
20. 10.1016/j.apt.2019.10.03110.1016/j.apt.2019.10.031 ↗
21. 10.1016/j.ijpharm.2015.12.07110.1016/j.ijpharm.2015.12.071 ↗
22. 10.1016/j.mser.2020.10054310.1016/j.mser.2020.100543 ↗
23. 10.1016/j.ijpharm.2020.11924510.1016/j.ijpharm.2020.119245 ↗
24. 10.1007/978-3-319-90755-0_210.1007/978-3-319-90755-0_2 ↗
25. ASTM Standard terminology for additive manufacturing technologies2012 F2792 ‐ 12a.
26. 10.1016/j.ijpharm.2018.07.02410.1016/j.ijpharm.2018.07.024 ↗
27. 10.1002/adfm.20200018710.1002/adfm.202000187 ↗
28. 10.1016/j.ejps.2018.02.00210.1016/j.ejps.2018.02.002 ↗
29. 10.1016/j.cej.2018.09.15910.1016/j.cej.2018.09.159 ↗
30. 10.2174/138161282566619050711550410.2174/1381612825666190507115504 ↗
31. 10.3390/pharmaceutics1004020310.3390/pharmaceutics10040203 ↗
32. 10.1016/j.matpr.2019.07.29610.1016/j.matpr.2019.07.296 ↗
33. 10.1007/978-3-319-90755-0_710.1007/978-3-319-90755-0_7 ↗
34. 10.1007/s11095-018-2556-510.1007/s11095-018-2556-5 ↗
35. C. W.Hull (3D Systems Inc) US 4575330A 1986.
36. 10.1016/j.ijpharm.2016.03.01610.1016/j.ijpharm.2016.03.016 ↗
37. 10.1016/S0142-9612(01)00243-510.1016/S0142-9612(01)00243-5 ↗
38. 10.1007/s10439-006-9156-y10.1007/s10439-006-9156-y ↗
39. 10.1007/978-3-319-90755-0_410.1007/978-3-319-90755-0_4 ↗
40. 10.1243/095441101153375110.1243/0954411011533751 ↗
41. 10.1016/S0142-9612(03)00030-910.1016/S0142-9612(03)00030-9 ↗
42. 10.1016/j.ijpharm.2017.06.08210.1016/j.ijpharm.2017.06.082 ↗
43. 10.1016/j.surfcoat.2019.12519210.1016/j.surfcoat.2019.125192 ↗
44. E. M.Sachs J. S.Haggerty M. J.Cima P. A.Williams US5204055A 1993.
45. 10.1007/978-3-319-90755-0_310.1007/978-3-319-90755-0_3 ↗
46. 10.1021/acsami.9b0811610.1021/acsami.9b08116 ↗
47. 10.1016/S0022-3913(08)60138-910.1016/S0022-3913(08)60138-9 ↗
48. 10.1016/j.cie.2018.07.04110.1016/j.cie.2018.07.041 ↗
49. 10.1016/j.ejpb.2014.12.00310.1016/j.ejpb.2014.12.003 ↗
50. 10.1016/j.ejpb.2019.05.01810.1016/j.ejpb.2019.05.018 ↗
51. 10.1208/s12249-018-1017-010.1208/s12249-018-1017-0 ↗
52. 10.1002/marc.20190042610.1002/marc.201900426 ↗
53. 10.1186/1743-8977-3-1110.1186/1743-8977-3-11 ↗
54. EMA Glossary ‐ Nanotechnology European Medicines Agency https://www.ema.europa.eu/en/glossary/nanotechnology(accessed: August 2020).
55. 10.1002/smll.20200015310.1002/smll.202000153 ↗
56. 10.1016/j.jconrel.2017.08.03310.1016/j.jconrel.2017.08.033 ↗
57. 10.3390/jpm704001210.3390/jpm7040012 ↗
58. 10.1016/j.ejpb.2012.10.01910.1016/j.ejpb.2012.10.019 ↗
59. 10.1515/ntrev-2016-010210.1515/ntrev-2016-0102 ↗
60. 10.3390/ijms2102053610.3390/ijms21020536 ↗
61. 10.1039/C7NR00835J10.1039/C7NR00835J ↗
62. 10.1016/j.ejps.2016.12.04310.1016/j.ejps.2016.12.043 ↗
63. 10.3390/ijms2015380610.3390/ijms20153806 ↗
64. 10.1007/s13204-018-0856-z10.1007/s13204-018-0856-z ↗
65. 10.1016/j.nlm.2013.08.00110.1016/j.nlm.2013.08.001 ↗
66. 10.1016/j.ejps.2015.07.01210.1016/j.ejps.2015.07.012 ↗
67. 10.1016/j.msec.2018.11.01310.1016/j.msec.2018.11.013 ↗
68. 10.1155/2018/623148210.1155/2018/6231482 ↗
69. 10.1016/j.jconrel.2015.10.04910.1016/j.jconrel.2015.10.049 ↗
70. 10.3390/cancers1105064010.3390/cancers11050640 ↗
71. 10.1002/tcr.20170006110.1002/tcr.201700061 ↗
72. 10.1166/jbn.2016.212210.1166/jbn.2016.2122 ↗
73. 10.1021/mp800051m10.1021/mp800051m ↗
74. 10.1016/j.jpba.2015.11.02710.1016/j.jpba.2015.11.027 ↗
75. 10.1002/advs.20160027910.1002/advs.201600279 ↗
76. 10.1016/j.ijpharm.2020.11942910.1016/j.ijpharm.2020.119429 ↗
77. 10.1038/s41467-018-06730-z10.1038/s41467-018-06730-z ↗
78. 10.1016/j.colsurfb.2019.05.00810.1016/j.colsurfb.2019.05.008 ↗
79. 10.1016/j.pmatsci.2020.10068610.1016/j.pmatsci.2020.100686 ↗
80. 10.1517/17425247.2013.76995610.1517/17425247.2013.769956 ↗
81. 10.1016/B978-0-323-46152-8.00006-810.1016/B978-0-323-46152-8.00006-8 ↗
82. 10.1080/21691401.2018.156145710.1080/21691401.2018.1561457 ↗
83. 10.1021/acsbiomaterials.0c0088310.1021/acsbiomaterials.0c00883 ↗
84. 10.1002/adtp.20190010210.1002/adtp.201900102 ↗
85. 10.1016/B978-0-12-814029-1.00018-110.1016/B978-0-12-814029-1.00018-1 ↗
86. 10.1016/j.ijpharm.2009.10.01810.1016/j.ijpharm.2009.10.018 ↗
87. 10.1590/S0100-4042200300050001710.1590/S0100-40422003000500017 ↗
88. 10.1016/j.ijpharm.2017.04.03610.1016/j.ijpharm.2017.04.036 ↗
89. 10.1016/B978-0-323-52727-9.00023-610.1016/B978-0-323-52727-9.00023-6 ↗
90. Dhas A. · Eur. J. Biomed. Pharm. Sci. · 2016 · 3 · 156
91. Junghanns J. U. A. H. · Int. J. Nanomed. · 2008 · 3 · 295
92. 10.3390/pharmaceutics1003013410.3390/pharmaceutics10030134 ↗
93. 10.1016/j.addr.2020.06.02010.1016/j.addr.2020.06.020 ↗
94. 10.1080/21655979.2020.173624010.1080/21655979.2020.1736240 ↗
95. 10.1016/j.cej.2018.11.14510.1016/j.cej.2018.11.145 ↗
96. 10.1016/j.cis.2019.10198910.1016/j.cis.2019.101989 ↗
97. 10.1186/s42833-019-0002-610.1186/s42833-019-0002-6 ↗
98. 10.1016/j.actbio.2019.11.02710.1016/j.actbio.2019.11.027 ↗
99. 10.1016/B978-0-323-46144-3.00023-410.1016/B978-0-323-46144-3.00023-4 ↗
100. 10.1039/C5RA03786G10.1039/C5RA03786G ↗